ホーム › 多発性骨髄腫 › ノースカロライナ › Durham
Durham、NCにおける多発性骨髄腫の臨床試験
Durhamとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する37件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
被験者募集中第3相
- Research Site, Chapel Hill · 10マイル先
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
被験者募集中第2相
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10マイル先
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
被験者募集中第3相
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
被験者募集中第2/3相
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10マイル先
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
被験者募集中第3相
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- University of North Carolina Medical Center, Chapel Hill · 10マイル先
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
被験者募集中第1/2相
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10マイル先
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
被験者募集中第2相
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13マイル先
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
被験者募集中第1/2相
- GSK Investigational Site, Chapel Hill · 10マイル先
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
被験者募集中第1相
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
被験者募集中第1/2相
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
被験者募集中第3相
- Research Site, Durham
- Research Site, Chapel Hill · 10マイル先
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
被験者募集中
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10マイル先
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
被験者募集中第1相
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
被験者募集中第2相
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10マイル先
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
被験者募集中第1/2相
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10マイル先
Selinexor and Backbone Treatments of Multiple Myeloma Patients
被験者募集中第1/2相
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- University of North Carolina /ID# 251203, Chapel Hill · 10マイル先
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
被験者募集中第1相
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
被験者募集中第2相
- University of North Carolina (Data Collection Only), Chapel Hill · 10マイル先
Registry of Older Patients With Cancer
被験者募集中観察研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
被験者募集中第3相
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
被験者募集中第2相
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1相
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10マイル先
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
被験者募集中第1/2相
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13マイル先
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- University of North Carolina, Chapel Hill · 10マイル先
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
被験者募集中第1相
- University of North Carolina, Chapel Hill · 10マイル先
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10マイル先
Registry for Adults With Plasma Cell Disorders (PCD's)
被験者募集中観察研究
- North Carolina Cancer Hospital, Chapel Hill · 10マイル先
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
被験者募集中観察研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
被験者募集中第1相
- Duke University Health System (DUHS), Durham
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
- Seattle, WA22件の研究
Durhamにおける他の研究
- 乳がん63件の研究
- がん（全種類）58件の研究
- 非小細胞肺癌39件の研究
- 転移性癌33件の研究
- 急性骨髄性白血病33件の研究
- 肺がん32件の研究
- 前立腺がん32件の研究
- 大腸癌28件の研究
- 慢性リンパ性白血病27件の研究
- 卵巣がん27件の研究
- 心不全26件の研究
- 膵臓がん24件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。